source
- Capricor Therapeutics sees stock surge as FDA signals openness to extend review of DMD cell therapyCapricor Therapeutics' CEO Linda Marbán told investors that the FDA is receptive to adding open label extension data to its Biologics License Application for deramiocel, its Duchenne muscular dystr…
- Drug-testing lab sues US Pharmacopeia over alleged false statements about testing methodsValisure, a laboratory known for testing drug impurities, has filed a lawsuit in a U.S. court accusing the United States Pharmacopeia (USP) of making false and misleading statements about its testi…